^
Association details:
| Biomarker: | EGFR underexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | serclutamab talirine (ABBV-321) (DNA replication inhibitor, EGFR-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
Excerpt:
The most sensitive cell lines are killed by ABBV-321 at subnanomolar to single-digit nanomolar concentrations, whereas most of the cell lines tested are largely insensitive to the MMAE ADC, ABBV-221 (Table 3), confirming that activity of ABBV-321 may extend to low and moderate- EGFR-expressing colorectal tumors, which are largely insensitive to auristatin-based ADCs.
DOI:
https://doi.org/10.1158/1535-7163.MCT-20-0149
